Pharma Mar SA (PHMMF) Price & Analysis

Compare

51 Followers

PHMMF Stock Chart & Stats

Day’s Range― - ―

52-Week Range$32.55 - $110.19

Previous CloseN/A

Volume3.60K

Average Volume (3M)0.00

Market Cap

$1.49B

Enterprise ValueN/A

Total Cash (Recent Filing)$140.85M

Total Debt (Recent Filing)€51.94M

Price to Earnings (P/E)68.5

Beta1.14

Next Earnings

Jul 24, 2025

EPS EstimateN/A

Next Dividend Ex-Date

Jun 25, 2025

Dividend Yield0.84%

Share Statistics

EPS (TTM)-0.25

Shares Outstanding18,222,227

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-2.70

Price to Book (P/B)6.62

Price to Sales (P/S)0.00

P/FCF Ratio-72.61

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$121.25

Price Target Upside45.45% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

---

Pharma Mar SA News

PremiumCompany Announcements

Pharma Mar S.A. Announces 2025 Shareholders’ Meeting with Key Agenda Items

8d ago

PremiumCompany Announcements

Pharma Mar SA Reports Strong Q1 2025 Revenue Growth

8d ago

PremiumCompany Announcements

PharmaMar Reports Strong Q1 2025 Financial Growth

19d ago

PremiumCompany Announcements

Pharma Mar Announces 2025 Shareholders Meeting with Key Governance Proposals

19d ago

PremiumPre-Earnings

Is PHMMF a Buy, Before Earnings?

22d ago

PremiumCompany Announcements

Pharma Mar SA Reports on Recent Share Buy-Back Activities

22d ago

PremiumCompany Announcements

Pharma Mar Adjusts Financial Strategy with New Share Buyback Program

1M ago

PremiumCompany Announcements

Pharma Mar’s Credit Rating Maintained at ‘BB+’

1M ago

See All PHMMF News

---

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

― Insiders

2.34% Mutual Funds

― Other Institutional Investors

93.77% Public Companies and

Individual Investors

Detailed Ownership Overview >

PHMMF FAQ

What was Pharma Mar SA’s price range in the past 12 months?

Pharma Mar SA lowest stock price was $32.55 and its highest was $110.19 in the past 12 months.

What is Pharma Mar SA’s market cap?

Pharma Mar SA’s market cap is $1.49B.

When is Pharma Mar SA’s upcoming earnings report date?

Pharma Mar SA’s upcoming earnings report date is Jul 24, 2025 which is in 71 days.

How were Pharma Mar SA’s earnings last quarter?

Pharma Mar SA released its earnings results on Apr 24, 2025. The company reported -$0.255 earnings per share for the quarter, missing the consensus estimate of -$0.125 by -$0.13.

Is Pharma Mar SA overvalued?

According to Wall Street analysts Pharma Mar SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharma Mar SA pay dividends?

Pharma Mar SA pays a Annually dividend of $0.889 which represents an annual dividend yield of 0.84%. See more information on Pharma Mar SA dividends here

What is Pharma Mar SA’s EPS estimate?

Pharma Mar SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pharma Mar SA have?

Pharma Mar SA has 18,222,227 shares outstanding.

What happened to Pharma Mar SA’s price movement after its last earnings report?

Pharma Mar SA reported an EPS of -$0.255 in its last earnings report, missing expectations of -$0.125. Following the earnings report the stock price went up 1.069%.

Which hedge fund is a major shareholder of Pharma Mar SA?

Currently, no hedge funds are holding shares in PHMMF

---

Pharma Mar SA Stock Smart Score

Outperform

Fundamentals

Return on Equity

10.15%

Trailing 12-Months

Asset Growth

-0.10%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

---

PHMMF Earnings Call

Q4 2025

0:00 / 0:00

---

PHMMF Stock 12 Month Forecast

Average Price Target

$121.25

▲(45.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"29":"$29","122":"$122","52.25":"$52.3","75.5":"$75.5","98.75":"$98.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":121.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$121.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":121.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$121.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":121.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$121.25</span>\n  </div></div>","useHTML":true}}],"tickPositions":[29,52.25,75.5,98.75,122],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2020","6":"Jan<br/>2023","9":"Aug<br/>2024","12":"Apr<br/>2025","25":"Apr<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.95,89.58846153846154,92.22692307692309,94.86538461538461,97.50384615384615,100.1423076923077,102.78076923076924,105.41923076923078,108.0576923076923,110.69615384615385,113.33461538461539,115.97307692307692,118.61153846153846,{"y":121.25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.95,89.58846153846154,92.22692307692309,94.86538461538461,97.50384615384615,100.1423076923077,102.78076923076924,105.41923076923078,108.0576923076923,110.69615384615385,113.33461538461539,115.97307692307692,118.61153846153846,{"y":121.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.95,89.58846153846154,92.22692307692309,94.86538461538461,97.50384615384615,100.1423076923077,102.78076923076924,105.41923076923078,108.0576923076923,110.69615384615385,113.33461538461539,115.97307692307692,118.61153846153846,{"y":121.25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":87.3,"date":1598918400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":87.3,"date":1601510400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":87.3,"date":1604188800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":87.3,"date":1604188800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":56.63,"date":1661990400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.62,"date":1664582400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.82,"date":1672531200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.95,"date":1680307200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.87,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.34,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >